ProPhase Labs, Inc. Announces Resignation of Mark Burnett from Board of Directors and All Committees of the Board Including Audit Committee
December 27, 2018 at 06:08 am EST
Share
On December 24, 2018, ProPhase Labs, Inc. notified that as a result of Mark Burnett's resignation from the Company's Board of Directors and all committees of the Board including the Audit Committee, effective December 21, 2018.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
